1-11 of 11
Authors: K Balampanis
Journal Article
Twelve-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus
European Heart Journal, Volume 45, Issue Supplement_1, October 2024, ehae666.2924, https://doi.org/10.1093/eurheartj/ehae666.2924
Published: 28 October 2024
Journal Article
Association of GDF15, NTpoBNP and PLGF with subclinical cardiac dysfunction in type 2 diabetes: effects of novel antidiabetic treatment
European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.2558, https://doi.org/10.1093/eurheartj/ehad655.2558
Published: 09 November 2023
Journal Article
Four-month treatment with long-acting glucagon-like peptide-1 receptor agonists (GLP-1) or sodium-glucose co-trasporter-2 inhibitors (SGLT-2i) improves vascular function in type 2 diabetes mellitus
European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.1940, https://doi.org/10.1093/eurheartj/ehac544.1940
Published: 03 October 2022
Journal Article
Four-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus
European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.2687, https://doi.org/10.1093/eurheartj/ehac544.2687
Published: 03 October 2022
Journal Article
Effect ofglucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on left atrial strain and arterial function
European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.2652, https://doi.org/10.1093/eurheartj/ehab724.2652
Published: 14 October 2021
Journal Article
The combination of dulaglutide and dapagliflozin improves arterial stiffness, endothelial glycocalyx and albuminuria vs DPP-4 inhibitors independently of glycemic control
European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.2648, https://doi.org/10.1093/eurheartj/ehab724.2648
Published: 14 October 2021
Journal Article
First-degree relatives of type-2 diabetic patients and dysglycaemic patients have impaired endothelial function due to decreased bioavailability of nitric oxide
European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.2645, https://doi.org/10.1093/eurheartj/ehab724.2645
Published: 14 October 2021
Journal Article
Sodium-glucose cotransporter-2 inhibitors and their combination with glucagon like peptide-1 receptor agonists improve endothelial glycocalyx and arterial stiffness in type-2 diabetes
European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.2376, https://doi.org/10.1093/ehjci/ehaa946.2376
Published: 25 November 2020
Journal Article
Glucagon like peptide-1 receptor agonists and their combination with sodium-glucose cotransporter-2 inhibitors improve myocardial deformation and work index in type-2 diabetes after 12-month treatment
European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.0115, https://doi.org/10.1093/ehjci/ehaa946.0115
Published: 25 November 2020
Journal Article
Effects of glucagon like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on vascular function and myocardial work index in patient with type-2 diabetes
European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.3066, https://doi.org/10.1093/ehjci/ehaa946.3066
Published: 25 November 2020
Journal Article
P4991Effects of the glucagon like peptide-1 receptor analogue, sodium-glucose co-transporter 2 and their combination on myocardial work index and vascular function in diabetes after 3-month treatment Get access
European Heart Journal, Volume 40, Issue Supplement_1, October 2019, ehz746.0169, https://doi.org/10.1093/eurheartj/ehz746.0169
Published: 21 October 2019
